Taysha Gene Therapies (TSHA) Stock Price, Quote, News & History

Comments

Taysha Gene Therapies Inc (TSHA) Stock Price, Quote, News & History

TSHANASDAQ

Trade with Public

$5.95

-0.05-0.83%

At close: Apr 16, 5:00 PM EST

$5.93

-0.0195-0.33%

After Hours: 7:44 PM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$5.86

Close

$5.95

Volume / Avg.

4.41M / 2.74M

Day Range

$5.75 - $6.02

52 Wk Range

1.13 - 6.04

Market Cap

$1.70B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

71

Short Interest

16.35%

Days to Cover

13.08

Recent Taysha Gene Therapies Inc News

Why Is Taysha Gene Therapies Stock Falling Friday?

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Vandana Singh

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

Vandana Singh

Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-93.09M

Investing Cash Flow (TTM)

-604.00K

Financing Cash Flow (TTM)

274.59M

Free Cash Flow (TTM)

-93.83M

Capital Expenditure (TTM)

-738.00K

Net Change in Cash (TTM)

180.90M

Analyst Trends and Forecast

1

Oct 25

1

Nov 25

2

Jan

3

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.47B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

196.28

PB Ratio (TTM)

6.98

Earnings Yield % (TTM)

-5.67%

Earnings Yield % (FWD)

-6.33%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.86

Company Debt

Total Debt

$50.11M

LT Debt

$50.11M

LT Debt Issuance (TTM)

$49.85M

LT Debt Repayment (TTM)

-$40.61M

Total Cash

$319.77M

Debt to Equity

0.28

Issuance of Debt (TTM)

$9.24M

Repayment of Debt (TTM)

-$40.61M

Key Statistics

Open

$5.86

Close

$5.95

Volume / Avg.

4.41M / 2.74M

Day Range

$5.75 - $6.02

52 Wk Range

1.13 - 6.04

Market Cap

$1.70B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

71

Short Interest

16.35%

Days to Cover

13.08

About

Sector

Health Care

Industry

Biotechnology

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in deve...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Taysha Gene Therapies (TSHA) stock?

A

You can purchase shares of Taysha Gene Therapies (NASDAQ:TSHA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Taysha Gene Therapies (TSHA) competitors?

A

Other companies in Taysha Gene Therapies’s space includes: Immatics NV (NASDAQ:IMTX), AnaptysBio Inc (NASDAQ:ANAB), Mesoblast Ltd (NASDAQ:MESO), Agios Pharmaceuticals Inc (NASDAQ:AGIO) and Tyra Biosciences Inc (NASDAQ:TYRA).

Q

What is the forecast, or price target, for Taysha Gene Therapies (TSHA) stock?

A

Taysha Gene Therapies has a consensus price target of $9.36.

Q

What is the current price for Taysha Gene Therapies (TSHA)?

A

The stock price for Taysha Gene Therapies (NASDAQ: TSHA) is $5.9305 last updated April 16, 2026 at 7:44 PM EDT.

Q

Does Taysha Gene Therapies (TSHA) pay a dividend?

A

There are no upcoming dividends for Taysha Gene Therapies.

Q

When is Taysha Gene Therapies (NASDAQ:TSHA) reporting earnings?

A

Taysha Gene Therapies does not have any upcoming earnings scheduled.

Q

Is Taysha Gene Therapies (TSHA) going to split?

A

There is no upcoming split for Taysha Gene Therapies.

Q

What sector and industry does Taysha Gene Therapies (TSHA) operate in?

A

Taysha Gene Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Agios Pharmaceuticals Inc

Sionna Therapeutics Inc

NASDAQ:SION

$45.24

%

Monte Rosa Therapeutics Inc

NASDAQ:GLUE

$18.76

0.32%

Olema Pharmaceuticals inc

NASDAQ:OLMA

$16.48

%

Key Statistics

Open

$5.86

Close

$5.95

Volume / Avg.

4.41M / 2.74M

Day Range

$5.75 - $6.02

52 Wk Range

1.13 - 6.04

Market Cap

$1.70B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

71

Short Interest

16.35%

Days to Cover

13.08

Recent Taysha Gene Therapies Inc News

Why Is Taysha Gene Therapies Stock Falling Friday?

Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial.

Vandana Singh

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

Vandana Singh

Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-93.09M

Investing Cash Flow (TTM)

-604.00K

Financing Cash Flow (TTM)

274.59M

Free Cash Flow (TTM)

-93.83M

Capital Expenditure (TTM)

-738.00K

Net Change in Cash (TTM)

180.90M

Analyst Trends and Forecast

1

Oct 25

1

Nov 25

2

Jan

3

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.47B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

196.28

PB Ratio (TTM)

6.98

Earnings Yield % (TTM)

-5.67%

Earnings Yield % (FWD)

-6.33%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.86

Company Debt

Total Debt

$50.11M

LT Debt

$50.11M

LT Debt Issuance (TTM)

$49.85M

LT Debt Repayment (TTM)

-$40.61M

Total Cash

$319.77M

Debt to Equity

0.28

Issuance of Debt (TTM)

$9.24M

Repayment of Debt (TTM)

-$40.61M

Key Statistics

Open

$5.86

Close

$5.95

Volume / Avg.

4.41M / 2.74M

Day Range

$5.75 - $6.02

52 Wk Range

1.13 - 6.04

Market Cap

$1.70B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

71

Short Interest

16.35%

Days to Cover

13.08

About

Sector

Health Care

Industry

Biotechnology

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in deve...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry